509 related articles for article (PubMed ID: 26783352)
1. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.
Ryoo JY; Yang HJ; Ji E; Yoo BK
Ann Pharmacother; 2016 May; 50(5):341-51. PubMed ID: 26783352
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Secukinumab for the Treatment of Psoriasis: A Meta-Analysis of Pivotal Phase III Trials.
Zhou Y; Zhang K; Ma X; Xie Z
Dermatology; 2024; 240(2):271-281. PubMed ID: 37926074
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab (AIN457) for the treatment of psoriasis.
López-Ferrer A; Vilarrasa E; Puig L
Expert Rev Clin Immunol; 2015; 11(11):1177-88. PubMed ID: 26428036
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
[TBL] [Abstract][Full Text] [Related]
6. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.
Bhat RM; Leelavathy B; Aradhya SS; Gopal MG; Pratap DV; Mubashir M; Srinivas P; Pande SY; Thavkar AS
Indian Dermatol Online J; 2017; 8(1):16-24. PubMed ID: 28217466
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
Körber A; Papavassilis C; Bhosekar V; Reinhardt M
Drugs Aging; 2018 Feb; 35(2):135-144. PubMed ID: 29404966
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
12. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis.
Armstrong AW; Feldman SR; Korman NJ; Meng X; Guana A; Nyirady J; Herrera V; Zhao Y
J Dermatolog Treat; 2017 May; 28(3):200-205. PubMed ID: 27541729
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
Wu NL; Hsu CJ; Sun FJ; Tsai TF
J Dermatol; 2017 Oct; 44(10):1129-1137. PubMed ID: 28493369
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
Adsit S; Zaldivar ER; Sofen H; Dei-Cas I; Maldonado-García C; Peñaranda EO; Puig L; Meng X; Fox T; Guana A
Adv Ther; 2017 Jun; 34(6):1327-1339. PubMed ID: 28397079
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
Gottlieb AB; Blauvelt A; Prinz JC; Papanastasiou P; Pathan R; Nyirady J; Fox T; Papavassilis C
J Drugs Dermatol; 2016 Oct; 15(10):1226-1234. PubMed ID: 27741340
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
[TBL] [Abstract][Full Text] [Related]
20. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
